Neurosense Therapeutics (NRSN) Ends its At-The-Market Equity Offering Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall Street ends mixed as investors focus on tech earnings
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices settle at lowest in over a week, as US pauses attacks on Iran
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- BuzzFeed cuts 35% of workforce in restructuring move
NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results
October 2, 2023 8:46 AM EDTTopline clinical data from ALS Phase 2b PARADIGM trial of PrimeC combination therapy is expected Q4 2023; Company is fully funded into Q2 2024
CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases,... More
